New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. The…
Adelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 – a conference which is organized annually by the…
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015 Bandung, Indonesia (Augus 26, 2015) – Innokeys Pte Ltd attended the…
Kowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….
Medical Oncology Group of Australia
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…